SOPHiA GENETICS SA Form 4 Filings

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported a small tax-related share sale. He sold 33 ordinary shares in an open-market transaction at $4.5424 per share to satisfy tax obligations from restricted stock units vesting on May 18, 2026. Following this sell-to-cover transaction, he directly holds 148,164 ordinary shares.

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu sold 4,000 Ordinary Shares in an open-market transaction at a weighted average price of $4.5421 per share. The sale was executed under a pre-established Rule 10b5-1(c) trading plan, and Xu held 626,888 shares directly after the transaction.

SOPHiA GENETICS SA director Kathy L. Hibbs reported an open-market sale of 7,508 Ordinary Shares on May 12, 2026. The shares were sold at a weighted average price of $4.6666 per share, in multiple trades between $4.54 and $4.85.

The transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c). Following this sale, Hibbs directly owns 89,768 Ordinary Shares. This represents a partial reduction of her holdings while retaining a substantial remaining position in the company.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported an open-market sale of 5,000 Ordinary Shares on May 12, 2026 at a weighted average price of $4.6689 per share. The transaction was made under a pre-arranged Rule 10b5-1(c) trading plan, and Menu now holds 256,388 shares directly.

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold 8,500 ordinary shares in an open-market transaction. The sale took place at a weighted average price of $5.0872 per share under a duly adopted Rule 10b5-1(c) trading plan. Following this transaction, he reports direct ownership of 3,633,981 ordinary shares.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu executed an open-market sale of 5,000 Ordinary Shares at a weighted average price of $4.8178 per share. Following this transaction, he directly holds 261,388 Ordinary Shares. The sale was made under a duly adopted Rule 10b5-1(c) trading plan.

SOPHiA GENETICS SA Chief People Officer Manuela Valente sold 380 ordinary shares in an open-market transaction. The shares were sold at a weighted average price of $5.2031 per share on April 20, 2026, and she held 215,071 shares afterward.

According to the disclosure, the sale was made solely to cover tax withholding obligations tied to restricted stock units that vested on April 18, 2026. The transactions were executed under a pre-established Rule 10b5-1(c) trading plan, meaning they were pre-planned and not discretionary market-timing trades.

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported an open-market sale of 608 Ordinary Shares at a weighted average price of $5.2053 per share. According to the disclosure, the shares were sold to satisfy tax withholding obligations tied to restricted stock units that vested on April 18, 2026.

The transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are described as non-discretionary. Following these sales, Xu directly holds 630,888 Ordinary Shares.

SOPHiA GENETICS SA Chief Legal Officer Van Well Daan sold 684 Ordinary Shares in an open-market transaction at a weighted average price of $5.1963 per share. The sale occurred on April 20, 2026 and was executed to cover tax withholding obligations from restricted stock units that vested on April 18, 2026.

The filing states that these transactions were carried out under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. After the sale, Van Well Daan directly owned 345,736 Ordinary Shares.

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported an open-market sale of 4,486 Ordinary Shares. The shares were sold on April 20, 2026 at a weighted average price of $5.205 per share, in multiple trades ranging from $5.08 to $5.29.

The sale was made to satisfy tax withholding obligations arising from restricted stock units that vested on April 18, 2026, under a pre-established Rule 10b5-1(c) trading plan and is described as non-discretionary. After the transaction, Camblong directly holds 3,642,481 Ordinary Shares.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported a small open-market sale of 608 ordinary shares of SOPH. The shares were sold at a weighted average price of $5.2002 per share and were made to satisfy tax withholding obligations tied to restricted stock units that vested on April 18, 2026.

These transactions were executed under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. After the sale, Menu directly holds 266,388 ordinary shares, indicating that the transaction affected only a very small portion of his overall position.

SOPHiA GENETICS SA President Ross Muken sold 760 Ordinary Shares in an open-market transaction. The shares were sold at a weighted average price of $5.2039 per share to cover tax withholding obligations from restricted stock units that vested on April 18, 2026.

The filing states these sales were made under a pre-established Rule 10b5-1(c) trading plan and are not discretionary trades. After this tax-related sale, Muken directly holds 681,672 Ordinary Shares, indicating the transaction is small relative to his reported position.

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported a small, non-discretionary share sale tied to taxes. On April 18, 2026, 33 Ordinary Shares were sold in the open market at an average price of $5.0816 per share to satisfy tax obligations from vesting restricted stock units. After this sell-to-cover transaction, he directly holds 148,197 Ordinary Shares.

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported an open-market sale of 600 ordinary shares on April 14, 2026 at a weighted average price of $4.9663 per share. The sale was executed under a pre-arranged Rule 10b5-1(c) trading plan, and Xu continued to hold 631,496 ordinary shares directly after the transaction.

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported routine share sales tied to tax obligations. On April 14 and 15, 2026, he sold a total of 60,602 ordinary shares in open-market transactions at weighted average prices of $4.9580 and $5.0021 per share. The filing states these sales were executed to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026, under a pre-established Rule 10b5-1(c) trading plan, meaning they were not discretionary trades. After these transactions, he continues to hold 3,646,967 ordinary shares directly.

Chief Medical Officer Philippe Menu of SOPHiA GENETICS SA sold 1,600 ordinary shares in an open-market transaction on April 14, 2026. The shares were sold at a weighted average price of $4.9581 per share under a pre-established Rule 10b5-1(c) trading plan.

Following this sale, Menu directly holds 266,996 ordinary shares. The transaction was executed through multiple trades at prices ranging from $4.78 to $5.16 per share.

SOPHiA GENETICS SA President Ross Muken completed an open-market sale of 2,800 Ordinary Shares at a weighted average price of $4.9597 per share. After this transaction, he directly holds 682,432 shares. The sale was made to cover tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026 and was executed under a pre-established Rule 10b5-1(c) trading plan, meaning it did not represent a discretionary trade.

SOPHiA GENETICS SA Chief Legal Officer Daan Van Well reported selling 2,400 Ordinary Shares of SOPH on April 10, 2026 at a weighted average price of $4.6672 per share. The footnotes state these shares were sold in the open market solely to satisfy tax withholding obligations from restricted stock units vesting on April 2 and 3, 2026.

The sales were executed under a pre-established Rule 10b5-1(c) trading plan and are described as non-discretionary. After the transaction, Van Well directly holds 346,420 Ordinary Shares, indicating he retained a substantial equity position in the company.

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported open‑market sales of 8,120 Ordinary Shares of SOPH. The shares were sold on April 10 and April 13, 2026 at weighted average prices around $4.68–$4.76 per share.

According to the disclosure, these sales were made to satisfy tax withholding obligations tied to restricted stock units that vested on April 2 and 3, 2026, and were carried out under a pre‑established Rule 10b5‑1(c) trading plan. Following the transactions, Xu continues to hold 632,096 Ordinary Shares directly.

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported open-market sales of 16,631 ordinary shares of SOPH. The shares were sold on April 10 and 13, 2026 at weighted average prices around $4.72–$4.76 per share.

Footnotes state these transactions were effected under a pre-established Rule 10b5-1(c) trading plan to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026, and are not discretionary trades. After these sales, Camblong continues to hold 3,707,569 ordinary shares directly.

SOPHiA GENETICS SA President Ross Muken reported two small open-market sales of Ordinary Shares to cover taxes from equity vesting. On April 10 and 13, 2026, he sold a total of 8,129 shares at weighted average prices around $4.69–$4.77 per share. A footnote explains these transactions were made to satisfy tax withholding obligations arising from restricted stock units that vested on April 2 and 3, 2026, and were executed under a pre-established Rule 10b5-1(c) trading plan, meaning they were not discretionary trades. Following the sales, he continues to hold 685,232 Ordinary Shares directly.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported small open-market sales of Ordinary Shares mainly to cover taxes from recent equity vesting. Across three transactions on April 10 and April 13, 2026, he sold a total of 8,125 shares at weighted-average prices around $4.68–$4.76 per share. The filing states these sales were made to satisfy tax withholding obligations tied to restricted stock units that vested on April 2 and 3, 2026 and were executed under a pre-established Rule 10b5-1(c) trading plan. After these transactions, Menu continues to hold 268,596 Ordinary Shares directly.

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported routine tax-related share sales. He sold 2,800 Ordinary Shares on April 8 at a weighted average of $4.8404 and 1,950 shares on April 9 at a weighted average of $4.7404 in open‑market transactions.

Footnotes state these sales were made solely to satisfy tax withholding obligations tied to restricted stock units that vested on April 2 and 3, 2026, under a pre‑established Rule 10b5‑1 trading plan. After these transactions, he continues to hold 3,724,200 Ordinary Shares directly.

SOPHiA GENETICS SA president Ross Muken reported open-market sales of ordinary shares primarily to cover taxes from equity compensation. On April 8 and 9, 2026, he sold a total of 4,736 shares at weighted average prices of about $4.84 and $4.74 per share. The filing states these trades were executed under a pre-established Rule 10b5-1 trading plan and were made to satisfy tax withholding obligations tied to restricted stock units that vested earlier in April. After these sales, Muken still directly holds 693,361 ordinary shares, indicating the transactions represent a small portion of his overall position.

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu sold 4,736 Ordinary Shares of SOPH in open-market transactions. The sales occurred on April 8 and 9, 2026 at weighted average prices of about $4.84 and $4.74 per share.

According to the disclosure, these shares were sold to cover tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026. The transactions were executed under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary. After the sales, Xu directly held 640,216 Ordinary Shares.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu disposed of 4,731 Ordinary Shares in open-market sales tied to tax obligations. On April 8, he sold 2,800 shares at a weighted average of $4.8370, and on April 9 he sold 1,931 shares at a weighted average of $4.7393.

The footnotes state these sales were made to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026 and were executed under a pre-established Rule 10b5-1 trading plan, meaning they were not discretionary trades. After these transactions, Menu directly holds 276,721 Ordinary Shares.

SOPHiA GENETICS SA Chief People Officer Manuela Valente reported an open-market sale of 3,824 Ordinary Shares on April 8, 2026 at a weighted average price of $4.849 per share. According to the disclosure, the shares were sold to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026.

The filing states these sales were executed under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary. After this transaction, Valente directly holds 215,451 Ordinary Shares of SOPHiA GENETICS SA.

SOPHiA GENETICS SA Chief Legal Officer Daan Van Well reported routine tax-related share sales. He sold a total of 4,849 Ordinary Shares in open-market transactions on April 8 and 9, 2026 at weighted average prices of $4.8452 and $4.7406 per share. According to the disclosure, these sales were made to satisfy tax withholding obligations from the vesting of restricted stock units under a pre-established Rule 10b5-1 trading plan and are not discretionary trades. After these transactions, he continues to hold 348,820 Ordinary Shares directly.

SOPHiA GENETICS SA Chief Financial Officer George Cardoza sold 1,403 ordinary shares of SOPH on April 8, 2026. The shares were sold in open-market transactions at a weighted average price of about $4.85 per share to cover tax withholding from recently vested restricted stock units.

According to the disclosure, these sales were made under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary. After these transactions, Cardoza directly holds 291,458 ordinary shares, indicating the sale represents a small portion of his overall position.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported routine share sales tied to equity compensation taxes. He sold a total of 5,100 Ordinary Shares in open-market transactions on April 6 and 7, 2026 at weighted average prices of $4.8505 and $4.8653 per share.

According to the disclosure, these sales were made to satisfy tax withholding obligations arising from restricted stock unit vesting on April 2 and 3, 2026 and were executed under a pre-established Rule 10b5-1 trading plan, rather than as discretionary trades. Following the sales, he directly holds 281,452 Ordinary Shares.

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert sold 624 Ordinary Shares of SOPH in open-market transactions. The sales occurred on April 6, 2026 at prices around $4.86 per share and were executed solely to cover tax obligations from recently vested restricted stock units.

After these tax-related sales, Puylaert directly holds 148,230 Ordinary Shares, indicating that only a very small portion of his equity position was used for the "sell to cover" transactions, which the company describes as non-discretionary rather than voluntary market trades.

SOPHiA GENETICS SA Chief Legal Officer Daan Van Well sold 5,105 Ordinary Shares of SOPH in early April 2026. The sales, at weighted average prices of about $4.86–$4.87 per share, were made in the open market to cover tax withholding obligations from recently vested restricted stock units.

According to the disclosure, these transactions on April 6 and 7, 2026 were executed under a pre-established Rule 10b5-1 trading plan and are not discretionary trades. After the sales, Van Well continues to hold more than 350,000 Ordinary Shares directly.

SOPHiA GENETICS SA president Ross Muken sold 5,024 Ordinary Shares in two small open-market transactions to cover taxes on recent equity vesting. On April 6 and 7, 2026, he sold 2,600 shares at a weighted average of $4.8474 and 2,424 shares at $4.8686.

The footnotes state these sales were made to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026, under a pre-established Rule 10b5-1 trading plan and were not discretionary trades. After these sales, he continues to hold 698,097 Ordinary Shares directly.

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong sold a total of 5,100 Ordinary Shares of the company in early April 2026. The transactions were open‑market sales made solely to cover tax withholding obligations triggered by the vesting of restricted stock units on April 2 and 3, 2026, under a pre‑established Rule 10b5‑1 trading plan and were not discretionary trades. Camblong sold 2,600 shares on April 6 at a weighted average price of $4.8517 and 2,500 shares on April 7 at a weighted average price of $4.8619, and continued to hold about 3.73 million Ordinary Shares directly after these sales.

SOPHiA GENETICS SA Chief Financial Officer George Cardoza reported small open-market sales of 4,933 Ordinary Shares to cover taxes on recent equity vesting. On April 6, he sold 2,520 shares at a weighted average price of $4.8456, followed by 2,413 shares on April 7 at a weighted average price of $4.8771. According to the disclosure, these trades were made under a pre-established Rule 10b5-1 trading plan and were executed to satisfy tax withholding obligations from restricted stock units that vested on April 2 and 3, 2026. After these transactions, he continues to hold 292,861 Ordinary Shares directly, indicating the sales represent a small, routine portion of his overall stake.

SOPHiA GENETICS SA Chief People Officer Manuela Valente reported open-market sales of company ordinary shares that were made to cover tax obligations from recent restricted stock unit vesting. The transactions, totaling 4,973 shares sold at prices around $4.85 per share, were executed under a pre-established Rule 10b5-1 trading plan.

Following these sales, Valente continues to hold 219,275 ordinary shares directly. Because the trades were specifically to satisfy tax withholding and were pre-planned, they reflect routine administration of equity compensation rather than discretionary buying or selling decisions.

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported open-market sales of ordinary shares tied to tax withholding on recently vested restricted stock units. The transactions covered a total of 5,100 shares at weighted average prices around $4.86 per share.

According to the disclosure, the sales were executed under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary trades to satisfy tax obligations. Following these transactions, Xu directly holds 644,952 ordinary shares.

SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma reported open-market sales of a total of 3,549 Ordinary Shares to cover tax obligations from recently vested restricted stock units. The sales on April 6 and 7, 2026 were executed under a pre-established Rule 10b5-1 trading plan and are described as non-discretionary.

After these transactions, Verma directly holds 204,400 Ordinary Shares.

SOPHiA GENETICS SA Chief Legal Officer Daan Van Well reported equity awards consisting of new options and restricted stock units tied to ordinary shares. The filing shows a grant of share options to purchase 142,216 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. A separate award granted 97,536 ordinary shares in the form of restricted stock units, with 25% of both the RSUs and options vesting on April 2, 2027 and the remainder vesting in installments through April 2, 2030. After these awards, Van Well is shown as beneficially owning 358,774 ordinary shares. This Form 4/A amends a prior report to correct the post-transaction ordinary share balance, which had been understated.

SOPHiA GENETICS SA President Ross Muken received new equity awards and corrected his reported share holdings. On April 2, 2026 he was granted options to buy 628,743 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036.

He also received 431,211 restricted stock units, each representing one ordinary share, bringing his directly held ordinary shares to 703,121 after the grant. The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030, contingent on continued service.

The share options vest 25% on April 2, 2027 and then in equal monthly installments through April 2, 2030. This amended filing corrects a prior report that had understated his post-transaction ordinary share holdings.

CARDOZA GEORGE reported acquisition or exercise transactions in this Form 4 filing.

SOPHiA GENETICS SA Chief Financial Officer George Cardoza received new equity awards and corrected a prior ownership figure. On April 2, 2026 he was granted options to buy 164,671 ordinary shares at $5.04 per share, vesting 25% on April 2, 2027 and then monthly through April 2, 2030. He also received 112,936 restricted stock units, with 25% vesting on April 2, 2027 and the remaining 75% in equal quarterly installments through April 2, 2030. After these awards, he beneficially owns 297,794 ordinary shares directly, correcting a previously reported amount of 112,936 shares that was described as an inadvertent error.

SOPHiA GENETICS SA Chief Executive Officer Jurgi Camblong reported awards of share-based incentives and corrected his reported holdings. He received a share option for 628,743 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036.

He was also granted 431,211 restricted stock units, each representing one ordinary share, under the 2021 Equity Incentive Plan. Following these grants, his beneficially owned ordinary shares are correctly reported as 3,734,050, revising a previously misstated amount in an earlier Form 4.

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu reported equity compensation grants consisting of options and restricted stock units tied to ordinary shares. He received a share option covering 164,671 ordinary shares at an exercise price of $5.04 per share, vesting 25% on April 2, 2027 and monthly through April 2, 2030. He also received 112,936 RSUs, each representing one ordinary share, vesting 25% on April 2, 2027 and the remaining 75% in equal quarterly installments through April 2, 2030, subject to continued service. Following these grants, his beneficial ownership of ordinary shares was corrected to 286,552 shares due to an earlier inadvertent reporting error.

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported equity compensation awards and corrected prior ownership data. He received a grant of 82,335 share options with a $5.04 exercise price expiring on April 2, 2036, plus 56,468 RSUs. The Form 4/A updates his beneficial ownership to 148,854 ordinary shares after these awards, amending an earlier filing that understated this amount.

SOPHiA GENETICS SA Chief People Officer Manuela Valente received new equity awards and corrected her reported share holdings. She was granted an option for 104,790 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036. She also received 71,869 restricted stock units, each representing one ordinary share, with 25% vesting on April 2, 2027 and the remaining 75% vesting in equal quarterly installments through April 2, 2030, subject to continued service. Following these awards and a correction to a prior report, her directly held ordinary shares are reported as 224,248.

SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported equity compensation grants and a correction to his reported holdings. He received a share option for 164,671 ordinary shares at an exercise price of $5.04 per share and a grant of 112,936 ordinary shares in the form of restricted stock units under the 2021 Equity Incentive Plan. The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. The option vests 25% on April 2, 2027, then in equal monthly installments through April 2, 2030, and expires on April 2, 2036. The amendment corrects his beneficial ownership after the transactions to 650,052 ordinary shares, instead of 112,936 shares previously reported due to an inadvertent error.

SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma reported equity awards and a correction to his reported holdings. He received a share option for 119,760 ordinary shares at an exercise price of $5.04 per share, expiring on April 2, 2036, and 82,136 restricted stock units representing future ordinary shares.

The option vests 25% on April 2, 2027, then in equal monthly installments through April 2, 2030. The RSUs vest 25% on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. The amendment also corrects his ordinary share holdings after the reported transactions to 207,949 shares, instead of 82,136 shares previously reported due to an error.

SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma received new equity awards as part of his compensation. He was granted options to buy 119,760 ordinary shares at an exercise price of $5.04 per share, vesting 25% on April 2, 2027 and monthly through April 2, 2030. He also received 82,136 restricted stock units, with 25% vesting on April 2, 2027 and the remaining 75% in equal quarterly installments through April 2, 2030. These are awards from the company, not open-market purchases or sales.

SOPHiA GENETICS SA granted President Ross Muken equity-based compensation on April 2, 2026. He received options to buy 628,743 ordinary shares at $5.04 per share, exercisable until April 2, 2036, and 431,211 restricted stock units that convert into ordinary shares as they vest.

According to the vesting terms, 25% of the RSUs vest on April 2, 2027, with the remaining 75% vesting in equal quarterly installments through April 2, 2030. The share options vest 25% on April 2, 2027, then in equal monthly installments through April 2, 2030, contingent on continued service.